Somnomed Limited · ASX:SOM
Somnomed — FY2011 Earnings Presentation
16 slides from Somnomed's earnings presentation, Aug 29, 2011
Slide 1: FY 2010 - 2011
For personal use only FY 2010 - 2011 This presentation contains forward-looking statements that involve risks and uncertainties. These forward-looking statements are not guarantees of SomnoMed's future performance and involve a number of risks and uncertainties that may cause actual results to diffe
Slide 2: Financial Overview, Highlights by Region, SomnoDent Outlook FY12
For personal use only 1 2 3 4 Financial Overview SomnoDent Outlook FY12 Highlights by Region G2 SomnoMed MATRx © SomnoMed 2011 2
Slide 3: Sales revenue, gross margin and EBITDA highlights
For personal use only Sales revenue* SomnoDent Gross Margin Group operating EBITDA Apnea unit improved to profit before + 15% to sales Corporate, + 268% to 66% A$12.34m compared to Research and A$0.99m + 28% to Development 25,119 56% in 2010 + 66% to devices A$3.06m * Revenue at +26.7% and A$13.5m o
Slide 4: FY 10/11 results versus prior years
For personal use only FY 10/11 FY 09/10 FY 08/09 FY 07/08 unaudited actual actual actual Devices # 25 119 19 543 12 254 7 033 Revenue A$ 12.4m 10.7m 7.7m 3.7m Operating Profit before Corporate, Research 3.1m 1.8m 0.02m (1.0m) and Development A$ Corporate, Research and Development A$ 2.3m 1.7m 1.8m 1
Slide 5: Operating profit by year
For personal use only FY 05/06 FY 06/07 FY 07/08 FY 08/09 FY 09/10 FY 10/11 $4,000 $3,061 $3,000 $1,897 $2,000 $1,000 $19 $A’000 $0 ($1,000) ($934) ($2,000) ($1,589) ($3,000) ($3,262) ($4,000) © SomnoMed 2011 5
Slide 6: Revenue, gross margin and EBITDA 2009-2011
For personal use only $30,000 Revenue Gross Margin Operating Profit before Corporate, Research and Development Overheads $25,000 EBITDA $20,000 $12,335 $A'000 $15,000 $10,714 $10,000 $7,737 $8,176 $5,000 $6,084 $4,059 $3,061 $1,897 $0 $18 $991 -$1,520 $270 2009 2010 2011 ($5,000) © SomnoMed 2011 6
Slide 7: Revenue and gross margin growth
For personal use only $25,000 CAGR Revenue 47% Gross Margin Revenues GM improvement from $20,000 57% to 66% in 2011 $15,000 $12,335 $A'000 $10,714 $10,000 $7,737 $5,000 $3,658 $8,176 $6,084 $1,786 $2,273 $4,059 $1,002 $1,957 $0 $801 FY 05/06 FY 06/07 FY 07/08 FY 08/09 FY 09/10 FY 10/11 © SomnoMed 20
Slide 8: Financial Summary ($000's)
For personal use only Financial Summary ( $000's ) 10/11* 09/10 08/09 07/08 06/07 Units 25,119 19,543 12,254 7,033 3,503 Revenue 12,335 10,714 7,737 3,658 2,273 Gross Margin 8,176 6,084 4,059 1,956 1,002 Operating profit/ (loss) before 3,061 1,842 19 (933) (1,588) corporate, research and development
Slide 9: Units sold per quarter and by region
For personal use only Units sold per quarter Unit contribution per region 8000 Total CAGR Units 58% 7000 6000 5000 4000 3000 2000 USA 25% 63% 1000 12% APAC EU 0 © SomnoMed 2011 9
Slide 10: Europe
For personal use only Europe Volume growth of more than 98% Expanded EU operation with HQ in Zurich and subsidiary in Sweden/Nordic Preparing for SomnoMed France and Germany Established market leadership position for OAT © SomnoMed 2011 10
Slide 11: Japan and Australia/New Zealand/Asia
For personal use only Japan SomnoMed Dental Network expanded by >60% Unit sales increased by 30% Australia/ New Zealand/ Asia Market leadership with SomnoDent No reimbursement for OSA treatment slows market development SomnoBrux sales increased by >100% © SomnoMed 2011 11
Slide 12: North America
For personal use only North America Record unit sales FY 10/11, accelerated in Q4 New and expanded HQ for North America in Dallas/Frisco Dental/Medical Territory Management Since January 2011 Medicare CMS ruling for Oral Appliance Treatment (OAT) © SomnoMed 2011 12
Slide 13: MATRx and SomnoDent G2
For personal use only | SomnoMed MATRx - a revolutionary breakthrough in the prediction of efficacy of an oral appliance in a full sleep study setting (PSG) | SomnoDent G2 - the next generation of the world’s # 1 oral sleep apnea appliance from early 2012 © SomnoMed 2011 13
Slide 14: FY12 outlook
For personal use only | Sales revenue > 25% | Apnea unit sales > 32,000 | Bruxism unit sales + 100% | SomnoMed Dental Network > 4,000 | Breakthrough product innovations to be launched in FY12: • The world’s first PSG Remote Controlled Mandibular Positioner • 2nd Generation of SomnoDent® Oral Applian
Slide 15: SomnoMed - The time is now. Thank-you
For personal use only SomnoMed®… The time is now... Thank-you © SomnoMed 2011 15
Slide 16: Contact details
For personal use only Chairman Address Telephone Dr Peter Neustadt Level 3, +61 (0)2 9467 0400 20 Clarke Street Chief Executive Officer Crows Nest NSW 2065 Website Mr Ralf Barschow Australia www.somnomed.com.au © SomnoMed 2011